HOCHDORF and Pharmalys are proud to announce the official launch of a new, jointly owned company, Hochdorf Laboratories SA. This strategic joint venture (JV), led by HOCHDORF, is a key milestone in HOCHDORF’s transformation, supported by its owner, AS Equity Partners.
The JV combines HOCHDORF’s world-class Swiss production technology and manufacturing expertise with Pharmalys’ powerful brand portfolio and established global market access. By integrating defined activities—including infant nutrition brands, intellectual property, and technical know-how—into one legal entity, the partnership will drive increased efficiency, faster decision-making, and sustainable, profitable growth.
The move aligns with AS Equity Partners’ strategy to leverage HOCHDORF’s operations on scalable, value-adding activities, international growth, while optimizing industrial utilization.
“The formation of this joint venture represents a decisive step forward in our vision for HOCHDORF. AS Equity Partners remains committed to providing the strategic and financial backing necessary to ensure this venture delivers long-term value for all stakeholders,” said Andreas Schulte, Founder and Managing Partner at AS Equity Partners.
“By bridging HOCHDORF’s industrial excellence with Pharmalys’ commercial strength, we are creating a high-performance platform poised for international expansion,” said Amir Mechria, Chairman of the Board at Pharmalys Laboratories.
.
